IL6 and cardiovascular disorder: Inhibitors targeting NLRP3 inflammasome as well as blockers of IL-8 and IL-6 (downstream of IL-1) are being clinically tested against a variety of cardiovascular diseases, and the discovery by Marchetti et al. [18] of a novel inhibitor derived from glyburide, a molecule that fails to induce insulin release, which significantly reduces the size of infarcts and protects cardiac function, also demonstrates that early NLRP3 inflammasome activation is critical for downstream inflammatory signaling.